Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,062 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anaemia Clear all
Completed Phase 2 Interventional

Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia

NCT00011505
View directory record Official record
Conditions
Diamond Blackfan Anemia
Interventions
G-CSF, Leukapheresis
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 4:57 AM EDT
Enrolling by invitation Not applicable Interventional

Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

NCT01881503
View directory record Official record
Conditions
Anemia
Interventions
HBOC-201
Biological
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

NCT01048905
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease, Thalassemia
Interventions
L-Glutamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
4 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Not listed Phase 1 Interventional

Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia

NCT00006127
View directory record Official record
Conditions
Fanconi's Anemia
Interventions
amifostine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

NCT01500161
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkins Disease, Non-Hodgkins Lymphoma, Aplastic Anemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Busulfan, Clofarabine, Fludarabine, Melphalan, Carmustine, Etoposide, Cytarabine
Drug
Lead sponsor
Texas Oncology Cancer Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease

NCT01369160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Quality of Life measures
Behavioral
Lead sponsor
Emory University
Other
Eligibility
3 Years to 23 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

NCT04606160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single Session Problem-Solving Intervention
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Not applicable Interventional

Delayed Cord Clamping in Premature Infants

NCT01018576
View directory record Official record
Conditions
Hypothermia, Anemia
Interventions
Delayed cord clamping
Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 1 Minute
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Results available

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

NCT03997760
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TAK-755, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Medical Treatment for Diamond Blackfan Anemia

NCT00001749
View directory record Official record
Conditions
Fanconi's Anemia, Hematologic Disease
Interventions
Antithymocyte globulin, Cyclosporine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

NCT00145626
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions
Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
Drug · Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225
View directory record Official record
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
Etavopivat
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Ocala, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Fitness Trial in Adults With Sickle Cell Disease (SCD Fit): A Feasibility Study

NCT04772391
View directory record Official record
Conditions
Cardiovascular Diseases, Sickle Cell Disease, Exercise
Interventions
Exercise Sessions
Other
Lead sponsor
Memorial Healthcare System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications

NCT02384590
View directory record Official record
Conditions
Sickle Cell Disease, Depression, Anxiety
Interventions
Computerized cognitive behavioral therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 22, 2026, 4:57 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06284460
View directory record Official record
Conditions
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
Interventions
ASTX029, ASTX727
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

NCT01522547
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study

NCT00661804
View directory record Official record
Conditions
Thalassemia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
5 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 22, 2026, 4:57 AM EDT
Withdrawn Phase 4 Interventional

Ketamine Infusion for Sickle Cell Pain Crisis

NCT04005209
View directory record Official record
Conditions
Anemia; Sickle-Cell, With Crisis, Acute Pain
Interventions
Ketamine, Pain management
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006
View directory record Official record
Conditions
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Ibrutinib
Other · Drug
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizuamb, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita

NCT01001598
View directory record Official record
Conditions
Fanconi Anemia, Dyskeratosis Congenita
Interventions
danazol
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Sickle Cell Hemoglobinopathies and Bone Health

NCT02306993
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Trait
Interventions
Healthy volunteers without SCT, Healthy volunteers with SCT, Volunteers with SCD
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 4:57 AM EDT